Independent corporate finance and investment advisory firm, specialising in smaller quoted and larger unquoted companies
The Directors of Byotrol plc (the “Company”) are pleased to be able to provide an update on the recent strong progress made across the group following the end of its financial year to 31 March 2007 and to report that direct product sales revenues will be in line with the Directors’ expectations and in the last quarter of the financial year #240,000 of sales orders were delivered.
The Company has made significant progress across all of its target markets in the year to 31 March 2007 and has been successful in attracting a number of new clients with global scale which the Directors believe will generate significant new sales revenue to the Company.
Within the UK industrial medical sector Byotrol is pleased to be able to announce it has recently shipped an order for more than 20,000 litres of Byotrol concentrates which will be used in a speciality medical application.
The Company is also working on a number of new applications for Byotrol where the Directors see significant opportunities for sale of Byotrol. By way of example, a number of leading UK agricultural distributors have recently placed orders with the Company for disinfectant and wipe products containing Byotrol’s technology. Similarly in the pet care niche, sales of a range of grooming products containing Byotrol in leading retailer Pets at Home have significantly exceeded projections and the product range was recently recognised as new product of the year by Pets At Home
The Company’s ongoing testing and validation programme has also made strong progress and the Directors are pleased to be able to announce the publication of a North American study detailing the positive effects of the Company’s Polysphere® product in battling multidrug-resistant organisms (“MDROs”). This study has resulted in the participating hospital incorporating Byotrol products into its cleaning regime and this represents a very encouraging step in penetrating the US healthcare market.
The study, carried out by hospital based researchers at Monroe Hospital, Bloomington, Indiana found that Polysphere® provided “residual disinfecting properties to surfaces that may become contaminated by MDROs” and that in particular it was “effective for up to three (consecutive) days post treatment”.
All surfaces were inoculated using Vancomycin Resistant Enterococcus faecalis (” VRE”) and Methicillin Resistant Staphylococcus Aureus (“MRSA”). The study found that for three consecutive days no growth of VRE occurred and that growth of MRSA was so sparse that it “could be considered no growth”.
The full text of the paper can be found by here
Commenting on the recent successes Byotrol plc Chief Executive David McRobbie said:
“These recent successes demonstrate our ability to commercialise an innovative technology and generate future revenue streams across our target markets. ” Equally pleasing is the successful study within North America because this validates our technology in another marketplace. Importantly the work at Monroe Hospital demonstrates our ability to establish a trial that proves the efficacy of our technology and to convert that into product sales in the highly demanding US healthcare market.”